Treatment of Alzheimer's disease: Recommendations and suggestions of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology;Tratamento da doença de Alzheimer: Recomendações e sugestões do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 4, 2005, Pages 1104-1112

  Engelhardt, Eliasz ^a,d   Brucki, Sonia M T ^b,c   Cavalcanti, José Luiz S ^a,d   Forlenza, Orestes V ^e   Laks, Jerson ^a,f   Vale, Francisco A C ^g  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UFRJ ^*  (Brazil)

^e Instituto de Psiquiatria FMUSP

^f STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^g Grupo de Neurologia do Comportamento CHMS RP

Author keywords

Alzheimer; Dementia; Treatment

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHOLINESTERASE INHIBITOR; DESIPRAMINE; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; LOFEPRAMINE; MEMANTINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OLANZAPINE; QUETIAPINE; RIVASTIGMINE; SEDATIVE AGENT; SELEGILINE; TACRINE; THIORIDAZINE;

AGING; ALZHEIMER DISEASE; BEHAVIOR; BRAZIL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROLOGY; REVIEW;

EID: 32244434603     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/s0004-282x2005000600035     Document Type: Review

References (111)

1. Summers WK, Majowski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-1245.
2. Qizilbash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA 1998;-280:1777-1782.
3. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996;7:293-303.
4. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
5. Birks JS, Melzer D, Beppu H, et al. Donepezil for mild to moderate Alzheimer's disease. In: Cochraine Library, Issue 2. Oxford: Update software, 2001.
6. Corey-Bloom J, Anand R, Veach J. A ramdomized trial evaluating the efficacy and safety of ENA 713 (Rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer disease for the ENA 713 B352 Study Group. Int J Geriatric Psychopharmacol 1998;1:55-65.
7. Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyrylcholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053-1065.
8. Birks J, Grimley EJ, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. In: Cochrane Library, Issue 2. Oxford: Update software, 2001.
9. Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic developmenta study of molecular forms. Neurochem Int 1992;21:381-396.
10. Maelicke A , Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer disease. Eur J Pharmacol 2000;393:165-170.
11. EngelhardtE, Bertolucci P, Brito-Marques P, et al. Eficácia da rivastigmina no desempenho cognitivo de pacientes com doença de Alzheimer provável leve a moderada: resultados do braço brasileiro de um estudo aberto multicêntrico (ENA-INT-01-BR). Arq Neuropsiquiatr 2003;61(Suppl):S54-S55.
12. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998;138:217-230.
13. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriat Pshychiatry 1999;14:3-47.
14. Caramelli P, Chaves MLF, Engelhardt E, et al. Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brasilian Multi-Center galantamine study (GAL-BRA-01). Arq Neuropsiquiatr 2004;62:379-384.
15. Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-564.
16. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:677-685.
17. Newhouse PA. Alzheimer's disease and the Cholinergic system: an introduction to clinical pharmacological research. In: Heston LL Progress in Alzheimer's Disease and Similar Conditions. Washington DC: American Psychiatric Press, 1997:213-231.
18. Wenk GL, Quack G, Moebius HJ, et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 2000;66:1079-1083.
19. Reisberg B, Doody R, Stöffler A, et al. A randomized, placebo-controlled study of memantine, an uncompetitive NMDAantagonist, in patients with moderate to severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
20. Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003;20:465-476.
21. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324.
22. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci 2002;99:12197-12202.
23. Zhou LJ, Zhu XZ. Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. J Pharmacol Exp Ther 2000;293:982-988.
24. SastreJ, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000;49:427-435.
25. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136-1139.
26. Luo Y. Ginkgo biloba neuroprotection: therapeutic implications in Alzheimer's disease. J Alzheimers Dis 2001;3:401-407.
27. Mix JA, Crews WD Jr. An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med 2000;6:219-229.
28. Mix JA, Crews WD Jr. Adouble-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 2002;17:267-277.
29. Rigney U, Kimber S, Hindmarch I. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res 1999;13:408-415.
30. Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology 2000;51:416-423.
31. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, doubleblind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327-1332.
32. Le Bars PL, Velasco FM, Ferguson JM, et al. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 2002;45:19-26.
33. Berman K e Brodaty H. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs 2004;18:807-825.
34. Sano M, Ernesto C, Thomas RG. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222.
35. Morris MC, Evans DA, Bienias JL, et al. Vitamin E and cognitive decline in older persons. Arch Neurol 2002;59:1125-1132.
36. Tabet N, Birks J, Grimley EJ, et al. Vitamine E for Alzheimer's disease (Cochrane Review). The Cochrane Library 2005; no 2.
37. Miller ER3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high dosage vitamin E supplemention may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
38. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003;1:CD000442.
39. Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
40. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-2826.
41. Tabet N, Feldmand H. Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev 2003;2:CD004031.
42. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63:1624-1628.
43. Reiss AB, Siller KA, Rahman MM, et al. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiol Aging 2004;25:977-989.
44. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-98.
45. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
46. Henderson VW, Benke KS, Green RC, et al. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103-105.
47. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007-1015.
48. Mulnard RA, Corrada MM, Kawas CH. Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment. Curr Neurol Neurosci Rep 2004;4:368-373.
49. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662.
50. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
51. Cheong JA. An evidence-based approach to the management of agitation in the geriatric patient. Focus 2004;2:197-205.
52. Schneider LS, Katz IR, Park S, et al. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry 2003;11:414-425.
53. Lanctot KL, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998;59:550-561
54. Sultzer DL. Psychosis and antipsychotic medications in Alzheimer's disease: clinical management and research perspectives. Dement Geriatr Cogn Disord 2004;17:78-90.
55. Fontaine CS, Hynan LS, Koch K, et al. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003;64:726-730.
56. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004;3:4.
57. Fujikawa T, Takahashi T, Kinoshita A, et al. Quetiapine treatment for behavioral and psychologicalogy symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiol 2004;49:201-204.
58. Laks J, Engelhardt E, Marinho V, et al. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq Neuropsiquiatr 2001;59:859-864.
59. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004;65(Suppl):S11-S15.
60. Scharre DW e Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2002;16:128-130.
61. Brodaty H, Ames D, Snowdon J, et al. Arandomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-143.
62. De Deyn PP, Rabheru K, Rasmussen A, et al. Arandomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
63. De Deyn PP, Jeste DV, Auby P, et al. Aripiprazole in dementia of the Alzheimer's type: Annual Meeting of the American Association for Geriatric Psychiatry. Honolulu, 2003.
64. Street Js, Clark WS, Gannon Ks, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities. Arch Gen Psychiatry 2000;57:968-976.
65. Street JS, Gannon KS, Kadam DL, et al. A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001;1(Suppl):S62-S70.
66. Tariot P, Schneider LS, Katz IR, et al. Quetiapine in nursing home re s idents with Alzheimer's dementia and psychosis. Annual Meeting of the American Association for Geriatric Psychiatry. Orlando; 2002.
67. Lemke MR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry 1995;56:354-357.
68. Olin JT, Fox LS, Pawluczyk S, et al. Apilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400-405.
69. Tariot PN. Valproate use in neuropsychiatric disorders in the elderly. Psychopharmacol Bull. 2003;37(Supl 2):116-128.
70. Porsteinsson A P, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997;5:344-351.
71. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003;11:434-440.
72. Reifler BV, Larson E, Teri L, et al. Dementia of the Alzheimer's type and depression. J Am Geriatr Soc 1986;34:855-859.
73. Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dmenetia of the Alzheimer type. Am J Geriatr Psychiatry 1994;2:352-354.
74. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990;157:894-901.
75. Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992;6(Suppl):S55-S64.
76. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized demented patients. Am J Psychiatry 2002;159:460-465.
77. Sultzer DL. Selective serotonin reuptake inhibitors and trazodone for the treatment of depression, psychosis, and behavioral symptoms in patients with dementia. Int Psychogeriatr 2000;12:245-251.
78. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737-746.
79. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebocontrolled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001;13:233-240.
80. Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997;38:246-252.
81. Mega Ms, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.
82. Cummings JL, Anand R, Koumaras B, et al. Behavioral benefits in Alzheimer's disease patients residing in a nursing home following 52 weeks of rivastigmine. Annual Meeting of the American Psychiatric Association. Chicago, 2000.
83. Cummings JL, Schneider LS, Tariot P, et al. Reduction of behavioral disturbances and cergiver distress by galantamina in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532-538.
84. Hanley IG, McGuire RJ, Boyd WD. Reality orientation and dementia: a controlled trial of two approaches. Br J Psychiatry 1981;138:10-14.
85. Baines S, Saxby P, Ehlert K. Reality orientation and reminiscence therapy: a controlled cross-over study of elderly confused people. Br J Psychiatry 1987;151:222-231.
86. Zanetti O, Metitieri T, Bianchetti A, Trabucchi M. Reality orientation therapy for patients with dementia: a longitudinal study. Neurobiol Aging 1998;4(Suppl):S102-S103.
87. Spector A, Orrell M, Davies S, et al. Reality orientation for dementia. 2 (Cochrane Review). The Cochrane Library, 2000.
88. De Vreese LP, Néri M, Fioravanti M, et al. Memory rehabilitation in Alzheimer's disease: a review of progress. Int J Geriatr Psychiatry 2001;16:794-809.
89. Kesslak JP, Nackoul K, Sandman CA. Memory training for individuals with Alzheimer's disease improves name recall. Alzheimer Res 1997;34:151-157.
90. Bird M, Kinsella G. Long-term cued recall of tasks in senile dementia. Psychol Aging 1996;11:45-56.
91. Farina E, Fioravanti R, Chiavari L, et al. Comparing two programs of cogntive training in Alzheimer's disease: a pilot study. Acta Neurol Scand 2002;105:365-371.
92. Zanetti O, Binetti G, Magni E, et al. Procedural memory stimulation in Alzheimer's disease: impact of a trining programme. Acta Neurol Scand 1997;95:152-157.
93. Clare L, Wilson BA, Carter G, et al. Intervening with everyday memory problems in dementia of Alzheimer type: an errorless learning approach. J Clin Exp Neuropsychol 2000;22:132-146.
94. Bourgeois MS, Burgio LD, Schulz R, et al. Modifying repetitive verbalization of community-dwelling patients with AD. Gerontologist 1997;37:30-39.
95. Abrisqueta-Gomez J, Canali F, Vieira VLD, et al. Alongitudinal study of a neuropsychological rehabilitation program in Alzheimer's disease. Arq Neuropsiquiatr 2004;62:778-783.
96. Ávila R, Bottino CMC, Carvalho IAM, et al. Neuropsychological Rehabilitation of memory déficits and activities of daily living in patients with Alzheimer's disease: a pilot study. Braz J Med Biol Res 2004;37:1721-1729.
97. Bird M, Kinsella G. Long-term cued recall of tasks in senile dementia. Psychol Aging 1996;11:45-56.
98. Thompson C, Briggs M. Support for carers of people with Alzheimer's type dementia. Cochrane Database Syst Rev 2000;2:CD454.
99. Acton GJ, Kang J. Interventions to reduce the burden of caregiving for an adult with dementia: a meta-analysis. Res Nurs Health 2001;24:349-360.
100. Huang HL, Shyu YI, Chen ST, et al. Apilot study on a home based caregiver training program for improving caregiver self-efficacy and decreasing the behavioral problems of elders with dementia in Taiwan. Int J Geriatr Psychiatry 2003;18:337-345.
101. Ostwald SK, Hepburn KW, Caron W, et al. Reducing caregiver burden: a randomized psychoeducational intervention for caregivers of persons with dementia. Gerontologist 1999;39:299-309
102. Gitlin LN, Corcoran M, Winter L, et al. Arandomized, controlled trial of a home environmental intervention: effect on efficacy and upset in caregivers and on daily function of persons with dementia. Gerontologist 2001;41:4-14.
103. Done DJ, Thomas JA. Training in communication skills for informal carers of people suffering from dementia: a cluster randomized clinical trial comparing a therapist led workshop and a booklet. Int J Geriatr Psychiatry 2001;16:816-821.
104. Hepburn KW, Tornatore J, Center B, et al. Dementia family caregiver training: Affecting beliefs about caregiving and caregiver outcomes. J Am Geriatr Soc 2001;49:450-457.
105. Magai C, Cohen CI, Gomberg D. Impact of training dementia caregivers in sensitivity to nonverbal emotion signals. Int Psychogeriatr 2002;14:25-38.
106. Gerdner LA, Buckwalter KC, Reed D. Impact of a psychoeducational intervention on caregiver response to behavioral problems. Nurs Res 2002;51:363-374.
107. Herbert R, Levesque L, Vezina J, et al. Efficacy of a psychoeducative group program for caregivers of demented persons living at home: a randomized controlled trial. J Gerontol B Psychol Sci Soc Sci 2003;58(Suppl):S58-67.
108. Teri L. Effects of caregiver training and behavioral strategies on Alzheimer's disease. In Swaab I, Wisniewski W, (ed). Alzheimer's disease and related disorders. New York: John Wiley & Sons Ltd, 1999:809-816.
109. Mohide EA, Pringle DM, Streiner DL, et al. A randomized trial of family caregiver support in the home management of dementia. J Geriatr Am Soc 1990;38:446-454.
110. Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placement of patients with Alzheimer's disease. JAMA 1996;276:1725-1731.
111. Wright LK, Litaker M, Laraia MT, et al. Continuum of care for Alzheimer's disease: a nurse education and counseling program. Issues Ment Health Nurs 2001;22:231-252.